The US Court of Appeals for the First Circuit concludes that a reverse payment need not be in cash (Loestrin)

On February 22, 2016, in the second federal appellate drug patent settlement ruling since the Supreme Court’s decision in FTC v. Actavis, 133 S. Ct. 2223 (2013), the U.S. Court of Appeals for the First Circuit vacated a lower court decision granting a motion to dismiss for defendants. Writing for a unanimous panel, Judge Juan Torruella unequivocally found that Actavis applied to not only cash payments but also other forms of consideration. Factual background The case involves oral contraceptive Loestrin 24. Earlier versions of Loestrin required patients to take tablets for 21 straight days, followed by a week of placebo pills (or skipped tablets). In re Loestrin 24 FE Antitrust Litigation, 2016 WL 698077, at *4 (1st Cir. Feb. 22, 2016) (Loestrin). Users of these earlier Loestrin

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteur

Citation

Michael A. Carrier, The US Court of Appeals for the First Circuit concludes that a reverse payment need not be in cash (Loestrin), 22 février 2016, e-Competitions February 2016, Art. N° 78533

Visites 363

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues